Document:

Exhibit 10.9

 

Tikun Olam IP Ltd.

c/o Trident Trust Company (Cayman) Ltd.

P.O. Box 847, Grand Cayman, KY1-1103

Cayman Islands

 

December 9, 2018

Tikun Olam Ltd.

183 Ibn Gvirol Street,

Tel Aviv, Israel

Attention: Mr. Tsachi Cohen, Director

 

Re: Amendment to
the License Agreement

 

Reference is made in this letter agreement
(the "Letter") to the License Agreement, dated as of April 13, 2017 (the "License Agreement"),
by and between Tikun Olam Ltd., an Israeli corporation ("Licensor"), and Tikun Olam IP Ltd., a Cayman Islands
company (the "Licensee") (each a "Party" and together, the "Parties").

 

Each of the Parties hereby agrees to the
following amendment of the License Agreement (the "First Amendment"):

 

		1.	All terms used herein and not defined shall have the meaning ascribed to them in the License Agreement.

 

		2.	A new Section shall be added after Section 3, as follows:

 

"3A. Additional Consideration
for Over the Counter Products Pharmaceutical Products

Notwithstanding the provisions
of Section 3 above, in the event that Licensee shall develop any Pharmaceutical Products which may be sold in any jurisdiction
within the Territory other than Canada (an "Applicable Jurisdiction") over the counter (i.e., without a need for
a doctor's prescription) (each an "OTC Product") then, if the OTC Product reasonably competes with a product with
substantially similar composition of active components sold by Licensor or any licensee of Licensor (other than Licensee) conducting
business in such Applicable Jurisdiction pursuant to an effective legal license, permit or similar authority, Licensee shall pay
to Licensor a royalty of two percent (2%) of the Net Sales of such OTC Product sold in the Applicable Jurisdiction (the "OTC
Royalties"). The OTC Royalties shall be paid to Licensor annually, no later than March 31st of each calendar
year with respect to the Net Sales recognized during the previous year. The payment shall be accompanied by a written report signed
by an officer or manager of Licensee, setting forth in reasonable detail the name of each OTC Product, the Applicable Jurisdiction
and the Net Sales of such OTC Product in such Applicable Jurisdiction during the relevant reporting period.

 

For the purpose of this Section
3A, the term "Net Sales" shall mean the revenue of Licensee generated from sales of all OTC Products in each Applicable
Jurisdiction for which OTC Royalties are due, whether such sales are evidenced by cash, check, credit, charge, account, barter
or exchange, net of returns, discounts and allowances, and shall not include any sales or use taxes, VAT, excise or similar taxes,
freight or delivery charges or other amounts collected on behalf of third parties."

 

		3.	The definition of “Pharmaceutical Product” in Exhibit A (Section 55)
of the License Agreement is hereby deleted in its entirety and replaced with the following:

 

    	 	1	 

     

    

 

" “Pharmaceutical
Product” shall mean, with respect to each jurisdiction in which it is sold or intended for sale (the "Applicable
Jurisdiction"), any cannabis-based product, compound or medicine which under the laws of the Applicable Jurisdiction would
be regulated and subject to approval and restrictions in the same manner and degree and for specific indications as an approved
or registered pharmaceutical product (“Pharmaceutical-Level Regulation”), whether or not prescribed or used
for that specific indication, and whether used or sold pursuant to a prescription or over the counter; provided, however, that
for purposes of this Agreement: (a) the following shall not be considered a “Pharmaceutical Product”: (i) cannabis
plants (including flowers) in their natural form; (ii) food supplements containing cannabis as part of their ingredients, unless
they are subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation; (iii) cosmetic products containing cannabis
as part of their ingredients, unless they are subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation; and (iv)
cannabis-based toothpastes, (b) cannabis-based extracts, oils and mixtures shall not be considered a “Pharmaceutical Product”,
unless and to the extent such extracts, oils or mixtures are or were subject in the Applicable Jurisdiction to Pharmaceutical-Level
Regulation or have potency levels equal to or higher than an identical or substantially similar product which is subject in the
Applicable Jurisdiction to Pharmaceutical-Level Regulation, and (c) notwithstanding the foregoing, in the event that identical
or substantially similar cannabis-based products can be sold in any Applicable Jurisdiction as both a pharmaceutical product which
is subject to Pharmaceutical-Level Regulation and as a medical or adult use cannabis product which is not subject to Pharmaceutical-Level
Regulation, for purposes of this Agreement, the form of such cannabis-based product which is permitted to be sold without being
subject to Pharmaceutical-Level Regulation shall not be considered a “Pharmaceutical Product”. "

 

		3.	Except for the provision which was amended in accordance with the terms of this First Amendment,
the remainder of the terms and conditions of the License Agreement shall continue in full force and effect and shall apply, mutatis
mutandis, to this First Amendment.

 

		4.	Miscellaneous. This Letter may be executed in multiple counterparts which, taken together,
shall constitute one and the same agreement. In the event of a conflict between the provisions of this Letter and the License Agreement,
the provisions of this Letter shall prevail. This Letter may be amended only with the written consent of all of the parties hereto.
This Letter shall be subject to Section 16.4 (Governing Law; Jurisdiction) and 16.5 (Dispute Resolution) as set forth in the License
Agreement.

 

Please indicate your agreement with the
above by signing and returning to us the enclosed copy of this Letter.

 

	 	Sincerely,
	 	 
	 	Tikun Olam IP Ltd.
	 	 	 
	 	By: 	/s/
    Berel Farkas
	 	 	Berel Farkas
	 	 	Director

 

	ACCEPTED AND AGREED AS OF	 
	THE DATE FIRST WRITTEN ABOVE:	 
	 	 
	Tikun Olam Ltd.	 
	 	 	 
	By: 	/s/ Tsachi Cohen	 
	 	Tsachi Cohen	 
	 	Director  	 

 

    	 	2Exhibit 10.10

 

AMENDED
AND RESTATED SUBLICENSE AGREEMENT (U.S.)

 

This Amended
and Restated Sublicense Agreement (this “Agreement”) is made effective as of January 12, 2018 (the “Effective
Date”) by and between TO Pharmaceuticals USA LLC, a Delaware limited liability company (“TOP”) and
Tikkun Pharma, Inc., a Delaware corporation (“TP”). Each of TOP and TP may be referred to as a “Party”
and collectively as the “Parties”. This Agreement amends, supersedes, and restates the prior Sublicense Agreement
between the parties dated September 11, 2017 (the “Prior Sublicense”) in its entirety, and the Prior Sublicense
shall have no further force or effect as of the Effective Date.

 

RECITALS

 

WHEREAS,
TOP and Bezalel Partners, LLC (“Bezalel”) previously entered into that certain Shareholder Agreement (the “SHA”)
dated as of September 11, 2017, pursuant to which Bezalel and TOP agreed to invest in TP;

 

WHEREAS,
the SHA required TOP to sublicense to TP certain rights in-licensed from Tikun Olam Ltd., an Israeli corporation with registration
number 514263771 (“TOL”) as set forth in the Prior Sublicense; and

 

WHEREAS,
TOP, Bezalel, and TP have agreed to have a separate entity control the development of certain rights previously sublicensed to
TP in the Prior Sublicense (specifically, those rights related to treatment of cancer indications), and so wish to amend and restate
the Prior Sublicense to clarify that TP’s sublicensed rights exclude such cancer-related rights, as set forth herein.

 

NOW,
THEREFORE, in consideration of the above and the promises and covenants contained herein and in the SHA, the Parties agree as follows:

 

		1.	DEFINITIONS.

 

1.1.        “Cannabis”
means indica, sativa or other forms of the marijuana and hemp plants, hemp products and any compounds, or mixtures or combinations
thereof, isolated or derived from marijuana, cannabis or hemp plants, along with any synthetic version of such compounds, mixtures,
or combinations.

 

1.2.         “Intellectual
Property” means any inventions, plant breeds, works of authorship, trademarks and service marks, including the goodwill
therein, trade secrets, know-how, documentation, and information, together with any worldwide rights in or to any of the foregoing
under patent, plant patent, plant breeders, copyright, trademark, trade secret, or other intellectual or industrial property laws.

 

1.3.        “Limited
Pharmaceutical Business” means the business, whether currently in existence or not, of producing, researching, developing,
promoting, marketing, selling, distributing and otherwise commercializing Pharmaceutical Products (as defined herein) included
in or derived from the Sublicensed IP, to prevent, manage and treat autoimmune diseases, disorders, or symptoms related thereto,
provided however, that the Limited
Pharmaceutical Business will not include any of the above as it relates to Crohn’s Disease, coeliac diseases, any type of
colitis (including without limitation microscopic and ulcerative colitis) and any and all digestive and Inflammatory Bowel Diseases
(IBD), each together with any disorders or symptoms related thereto.

 

1.4.        “Pharmaceutical
Products” means any product, compound, medicine or therapeutic which is subject to regulation as a drug, medicine or
controlled substance by the United States Food and Drug Administration.

 

    	 	1 	 

     

    

 

1.5.        “Sublicensed
IP” means any intellectual property, whether registered or applied for, including patents, patent applications, plant
patents and plant patent applications, continuation and continuation in part applications and patents maturing therefrom, and divisional
applications and patents maturing therefrom, Sublicensed Marks (as defined herein), copyrights, promotional materials, know-how,
trade secrets, knowledge, documentation, information relating to clinical or other trials, patient data, plant breeders rights,
registered and unregistered Cannabis varieties and uniquely identifiable strains of Cannabis in all forms (as further detailed
hereunder) that are currently licensed to TOP from TOL under the TOL License, or that may be subsequently licensed to TOP from
TOL, or that are or may subsequently be otherwise developed or acquired at any time by TOP. For avoidance of doubt, for all Sublicensed
IP sublicensed to TP by TOP under the TOL License, in no event shall the scope of rights in such Sublicensed IP extend beyond the
rights licensed by TOL to TOP pursuant to the TOL License. For the avoidance of doubt, any intellectual property developed or acquired
by TP at any time outside the scope of the rights sublicensed under this Agreement shall not be Sublicensed IP.

 

1.6.        “Sublicensed
Marks” means the TOL-owned trademarks, trade names, logos, service marks, designs, emblems, signs, slogans, other similar
designations of source or original and general intangibles of like nature, whether registered, applied for or not, together with
the goodwill relating thereto.

 

1.7.        “Term”
has the meaning given to it in Section 3.1.

 

1.8.        “TOL
License” means the License Agreement between TOL and TOP dated as of April 13, 2017.

 

2.           SUBLICENSED
IP.

 

2.1.         Grant.

 

a.      TOP
grants to TP a perpetual, non-revocable (subject to the terms hereof), fully paid, royalty-free, exclusive sublicense to make,
have made, use, sell, have sold, offer for sale, import, reproduce, distribute, display, perform, create derivatives work from,
and otherwise fully use and exploit the Sublicensed IP in the United States in connection with the Limited Pharmaceutical Business.
For avoidance of doubt, to the extent TOP develops or acquires any Sublicensed IP after the Effective Date that is not owned by
TP, such Sublicensed IP shall be automatically sublicensed by TOP to TP pursuant to this Section 2.1(a). The aforesaid sublicense(s)
shall not be further sublicensable without the express written consent of TOP, which will not be unreasonably withheld, delayed,
or conditioned. For the avoidance of doubt, TP may engage third parties to assist in developing and commercializing Pharmaceutical
Products in connection with the Limited Pharmaceutical Business (“TP Contractors”).

 

b.      TP
shall not contest the TOL License, the Intellectual Property covered by the TOL License, the validity of the Sublicensed IP or
the rights of TOL or TOP in the Sublicensed IP, except in relation to any claims asserted by TOL or TOP against TP or an affiliate
thereof.

 

c.      TP
shall not use the Sublicensed IP in any fashion that would cause confusion with, dilute or damage the reputation or image of TOL
or TOP, their products or services; provided,
however, that TP shall not be considered to be in breach of this section as a result of the sale by TP of Pharmaceutical
Products bearing the TOL name or other TOL trademarks.

 

d.      Condition
Subsequent. The Parties agree that TOP shall use its reasonable efforts seek the written consent to this Agreement by
TOL, provided, that (i) such consent
shall not be required to close this Agreement and (ii) the Parties hereto agree to make any reasonable amendments that may be required
by TOL.

 

    	 	2 	 

     

    

 

2.2.        Exclusivity.
The Parties acknowledge that the TOL License grants TOP certain exclusive rights, which TOP is hereby sublicensing exclusively
to TP solely under Section 2.1. If TOL breaches or attempts to breach its obligation of exclusivity by licensing any of the Sublicensed
IP to any third party for use in connection with the Limited Pharmaceutical Business, TOP will promptly take all reasonable action,
up to and including filing a lawsuit on its and TP’s behalf, to prevent such breach of exclusivity. If TOP fails to take
such action, TP may, at its sole expense, file suit on behalf of itself and the applicable TOP and, if reasonably necessary for
standing or other legal reasons, TOP will join such suit.

 

2.3.        Sublicensed
Marks.

 

a.     The
Parties recognize the value of the goodwill associated with the Sublicensed Marks, and acknowledge that the Sublicensed Marks and
all rights therein, as well as the goodwill which accrues during the term of this Agreement, belongs exclusively to TOL, and TP
shall not acquire any rights in the Sublicensed Marks, other than as expressly granted in this Agreement. TP shall not do anything
inconsistent with TOL's ownership of its Sublicensed Marks. In particular, but without limitation, TP shall not attack the validity
of the Sublicensed Marks or TOL's rights in and to its Sublicensed Marks except in relation to any claims asserted by TOL or TOP
against TP or an affiliate thereof.

 

b.     TP
shall not misuse or misappropriate any of the Sublicensed Marks. TP shall not engage in any conduct that impairs or might tend
to impair the validity or enforceability of any of the Sublicensed Marks or any registrations of any of the Sublicensed Marks,
or that dilutes or might dilute the distinctive quality of any of the Sublicensed Marks, or that disparages or might disparage
any of the Sublicensed Marks. Notwithstanding anything to the contrary contained elsewhere in this Agreement, TP may not use any
of the Sublicensed Marks on any materials or products unless it has received TOL’s prior written approval for such use, except
that TP shall not be required to obtain such approval in connection with the use of Sublicensed Marks on materials or products
which does not materially differ from previously approved uses.

 

c.     In
addition to each Party’s other rights and remedies under this Agreement or otherwise, upon receipt of notice from TOL, TP
shall immediately discontinue any use of, and remove from its premises, all materials bearing any of the Sublicensed Marks, including
any signs, labels, stationery, advertising, promotional material and literature that, in the reasonable opinion of TOL, constitutes
an improper use of the Sublicensed Marks or reflects non-negligibly adversely on TOL’s reputation or brand image or any of
its corporate affiliates or partners or on any of its products or services.

 

d.     All
graphics, trademarks, service marks, trade names, trade dress, word marks, design marks, slogans and domain names, and all images,
logos, artwork, text and other works of authorship (collectively, the “Marks”)
that include or refer to the Sublicensed Marks, shall belong exclusively to TOL or TOP as the case may be and all use of the Marks
by TP, and the goodwill thereto, shall inure to their benefit.

 

e.     TP
agrees to affix to all Pharmaceutical Products, and related promotional and packaging materials, for sale to third parties (and
not Pharmaceutical Products held for internal use) that utilize the Sublicensed Marks, such Sublicensed Marks and notices as shall
be reasonably requested by TOP, to the extent practicable and consistent with commercial practice. TP agrees to obtain specific
written instructions with respect to the content and placements of all such notices. At all times when TP commercially uses the
Sublicensed Marks, to the extent practicable and consistent with commercial practice, TP shall note that its use is made under
license and shall indicate the owner of the Sublicensed Marks.

 

    	 	3 	 

     

    

 

f.     TP
agrees that TOP shall have the right, at all reasonable times, upon no less than fifteen (15) Business Day’s prior written
notice to TP, to inspect the premises, and books and records owned by or under the control of TP during regular business hours
as TOP considers necessary in order to verify TP’s compliance with the terms hereof, including for appropriate quality control
with respect to TP’s use of the Sublicensed Marks.

 

g.     Notwithstanding
the foregoing, the sublicense granted to TP hereunder is not intended to be, and shall not be construed as, an assignment by TOL
or TOP to TP, in part or in whole, of the ownership of the Sublicensed IP.

 

h.     The
Parties recognize that, notwithstanding anything implicitly or explicitly to the contrary in this Agreement, the sublicense granted
hereunder does not grant any rights with respect to any use of the Sublicensed IP other than with respect to the Limited Pharmaceutical
Business within the Territory.

 

2.4.        Commercialization
Plan.

 

a.     On
or before June 11, 2018, TP shall prepare, in consultation with TOP, and provide to the board of directors of TP (the “Board”)
a mutually acceptable commercialization plan (including the revised annual Commercialization Plans referenced below, the “Commercialization
Plan”) covering the development and commercialization of the Sublicensed IP for the Limited Pharmaceutical Business, in accordance
with applicable law and setting forth the specific activities and delivery dates thereunder. For the purposes of clarification,
the Commercialization Plan will include but not be limited to (i) a selection, or process for selection, of one or more indications
to pursue based on the data in-hand or known at such time, (ii) a list of appropriate studies with specific Cannabis-related indications
and deadlines for initiating one or more such studies, (iii) a list of one or more inventions for which patent rights should be
pursued if appropriate; and (iv) brand management, opportunity assessment, pricing, forecasting, market analysis, tactics and strategies.
The Parties shall cooperate in good faith to update the Commercialization Plan annually within sixty (60) days after the end of
each calendar year during the Term. Upon submission, the Board will have up to thirty (30) calendar days to review such plan. With
respect to the Commercialization Plan, subject to a thirty (30) calendar day cure period, a breach of this Section 2.4 will be
deemed material breach of this Agreement.

 

b.     TP
shall use its commercially reasonable efforts to promote and develop the Limited Pharmaceutical Business in accordance with the
Commercialization Plan and shall be responsible for all costs and expenses incurred in connection with developing and commercializing
Pharmaceutical Products in connection with the Limited Pharmaceutical Business. For the avoidance of doubt, any failure to substantially
implement any annual Commercialization Plan in accordance with the terms and schedule thereof shall be considered a material breach
of this Agreement.

 

2.5.        Information.
From time to time, upon TP’s request, TOP will provide a list of the Sublicensed IP and other information reasonably necessary
to allow TP to exercise its rights granted in Section 2.1. TOP will promptly notify TP if the scope of the Sublicensed IP as it
pertains Limited Pharmaceutical Business is materially increased or decreased, and notwithstanding anything to the contrary herein,
TP will not be liable for any acts or omissions caused by TOP’s delay in providing such notice.

 

3.           TERM
AND TERMINATION.

 

3.1.        Term.
This Agreement commences on the Effective Date and continues until the earliest of: (i) termination by any Party in accordance
with Section 3.2 below, or (ii) the date on which the last of the Sublicensed IP expires or is otherwise no longer effective (the
“Term”).

 

    	 	4 	 

     

    

 

3.2.        Termination.
Either Party may terminate this Agreement immediately upon: (i) a material breach of this Agreement by the other Party, if such
breach is not cured within thirty (30) calendar days after written notice from the non-breaching Party; or (ii) a voluntary petition
in bankruptcy is filed by the other Party, an involuntary petition in bankruptcy is filed with respect to the other Party, or any
petition, application or other pleading is filed or any proceeding is commenced seeking he appointment of a trustee, receiver or
liquidator for the other Party.

 

3.3.        Effect
of Expiration or Termination. Upon the expiration of this Agreement or its termination by TOP, TP shall cease and thereafter
refrain from all use of the Sublicensed IP, including the Sublicensed Marks, except that TP shall have thirty (30) calendar days
from expiration or termination of this Agreement to discontinue use and registration of the term “Tikun” as part of
its trade name. Upon the termination of this Agreement by TP pursuant to Section 3.2, all licensed rights in the Sublicensed IP
will automatically become perpetual and irrevocable for as long as any such right is granted by TOL: (i) to TOP; (ii) to an entity
affiliated with TOL or TOP or with substantially similar ownership; or (iii) to any other entity if such grant of rights is intended
to avoid this provision. Upon any expiration or termination of this Agreement, the Receiving Party of any Confidential Information
shall also destroy or return all Confidential Information to the Disclosing Party.

 

3.4.        Survival.
Sections 3.3, 4, 8, 9 and 10 of this Agreement will survive any termination or expiration of this Agreement.

 

4.           CONFIDENTIALITY.

 

4.1.        Definition.
“Confidential Information”
means any and all proprietary, non-public information disclosed by one Party (the “Disclosing
Party”) to another Party (the “Receiving
Party”) which a reasonable person would understand to be confidential, including without limitation technical,
financial, and other business information. For the avoidance of doubt, this Agreement and the TOL License shall be considered Confidential
Information.

 

4.2.        Obligations.
The Receiving Party will hold the Confidential Information in confidence using at least the same degree of care it uses to protect
its own confidential information, but in no event less than reasonable care. The Receiving Party will only use Confidential Information
as needed to exercise its rights under this Agreement, and will only disclose Confidential Information to its affiliates, directors,
officers, employees and contractors, as well as its financial and legal advisors and potential investors, who have a need to know
such Confidential Information in connection with this Agreement and who are bound by confidentiality obligations at least as restrictive
as those contained herein. Any disclosure of the TOL License in accordance with this Section shall be subject to the prior written
consent of TOP, which consent will not be unreasonably withheld or delayed.

 

4.3.        Exceptions.
Confidential Information does not include information that the Receiving Party can demonstrate is: (i) in the public domain or
subsequently enters the public domain through no fault of the Receiving Party; (ii) disclosed to the Receiving Party by a third
party without any breach of confidentiality obligations; (iii) known to the Receiving Party at the time of disclosure by the Disclosing
Party; or (iv) developed independently by the Receiving Party, without use of or reference to any Confidential Information of the
Disclosing Party. The Receiving Party may disclose Confidential Information to the extent necessary to comply with a valid legal
or government order or requirement, provided that it will provide the Disclosing Party reasonable prior notice and cooperate with
the Disclosing Party (at the Disclosing Party’s sole expense) with any reasonable effort to challenge or limit the ordered
or requested disclosure.

 

    	 	5 	 

     

    

 

4.4.        Publicity.
The Parties shall reasonably cooperate in connection with issuing press releases or promotional or marketing material to the
public or third parties in connection with the provisions of this Agreement; provided that
TP will have the right to issue press releases related to the studies and other commercial activities it conducts, provided,
further, that neither Party will publish any Confidential Information without the prior written consent of the
other Party, which consent will not be unreasonably withheld, delayed, or conditioned. TP shall not refer to either TOP or
TOL in any such releases or materials without the prior written consent of such entity, which will not be unreasonably
withheld or delayed.

 

5.          OWNERSHIP.

 

5.1.        Developments.
Except as may be limited by the TOL License, the Intellectual Property in all improvements and modifications of the Sublicensed
IP developed or acquired by TP, with or without involvement of TOP, in relation to the Limited Pharmaceutical Business (collectively,
“New IP”) will be owned by TP, and TOP hereby assigns and will be automatically deemed to have assigned, to
TP any right, title and interest it may have in and to such New IP. TP hereby grants, and will automatically be deemed to grant,
to TOP, a perpetual, royalty free, non-exclusive license to use and exploit such New IP outside of the Limited Pharmaceutical
Business. To the extent a TOL License prohibits such ownership of certain New IP, such New IP will be automatically be assigned
to either TOP or TOL as required by the TOL License and deemed part of the Sublicensed IP for purposes of the sublicense granted
in Section 2.1.

 

5.2.        Enforcement;
Patent Prosecution. TP will be responsible for, at its sole expense and control, using commercially reasonable efforts
to: (i) prosecute patents, copyrights, and trademarks for New IP owned by TP; and (ii) protect the New IP from material third
party infringement, violation, or misappropriation in connection with the Limited Pharmaceutical Business; provided in each case
that TOP will provide all reasonably necessary cooperation and information in such efforts by TP, and TOP will join such suit(s)
if required for TP to have legal standing in such litigation. Any award solely with regards to any New IP will be distributed
entirely to TP.

 

6.           REPRESENTATIONS
AND WARRANTIES.

 

6.1.        Mutual.
Each Party represents and warrants that: (i) it is an entity duly organized, validly existing, and in good standing under the laws
of its jurisdiction of formation; (ii) it has all requisite power and authority to enter into this Agreement and consummate the
transactions contemplated herein; and (iii) the execution, delivery, and performance of this Agreement does not and will not conflict
with any violation of applicable law or of any other agreements with a third party.

 

6.2.        TOP.
TOP represents and warrants that: (i) it is the lawful licensee of the Sublicensed IP and, has sufficient authority to grant
TP the sublicenses granted under this Agreement; (ii) that the execution, delivery, and performance by it of this Sublicense
Agreement does not require the approval of any governmental authority nor the application for or filing of or for any
license, permit, approval, waiver, no action, or similar permission from any governmental authority; (iii) it has not entered
into any additional sublicenses or other arrangements that may limit its rights or the rights of TP under this Agreement or
which may reasonably be expected to lead to a claim of infringement or invalidity regarding any portion of the Sublicensed IP
or its use; (iv) it has no knowledge of infringement of, or conflict with, any license or other intellectual property right
of any other third-party, and there is no known claim pending, filed or threatened related to infringement, ownership,
misappropriation, or invalidity regarding the Sublicensed IP or its use; and (v) it has not granted and will not at any time
during the Term grant or permit to exist any sublicense or other contingent or non-contingent right, title or interest under
or relating to the Sublicensed IP in connection with the Limited Pharmaceutical Business to any individual or entity, that
does or will conflict with or otherwise undermine or impair the exclusive rights of TP hereunder. Notwithstanding the
foregoing, TOP may use or sublicense the Sublicensed IP outside of the Limited Pharmaceutical Business.

 

    	 	6 	 

     

    

 

6.3.        TOL
License. TOP hereby covenants that it will not take any acts, or fail to act, in any way that results in a material
modification, limitation, loss, or termination of the rights granted by TOL that are sublicensed hereunder.

 

7.           INFRINGEMENT
BY THIRD-PARTIES.

 

7.1.        Report
of Infringement. With respect to any Sublicensed IP, when information comes to the attention of TP to the effect that
any of the licensed rights have been or are threatened to be infringed by a third party, TP shall promptly notify TOP in writing
of any such infringement or threatened infringement of which it has become aware.

 

7.2.        Enforcement.
TOP or TOL, as applicable, will take, at its own expense, any action it deems advisable in good faith to protect the Sublicensed
IP. In the event of an infringement or threatened infringement by a third party of the Sublicensed IP, TOP or TOL, as applicable,
shall have the exclusive option to direct and control the litigation and any settlement thereof. TP shall cooperate at its own
expense with TOP in protecting and defending the Sublicensed IP. In the event that neither TOP nor TOL prosecutes such alleged
infringement or violation of the Sublicensed IP, TP shall have the right, but not the obligation, to enforce such Sublicensed IP
at its own expense. TOP hereby agrees, on their own behalf and on behalf of TOL, to join in such suit if required for proper standing.
If TP has brought such an action, any award will be distributed entirely to TP.

 

8.          INDEMNIFICATION.

 

8.1        By
TOP. TOP will indemnify, defend, and hold harmless TP, and its officers, directors, members, managers, and employees
from any losses, liabilities, damages, penalties, awards, settlements, costs, and expenses, including reasonable attorneys’
fees, (collectively, “Losses”) incurred in relation to a third-party claim arising out of any: (i) gross negligence,
willful misconduct, or violation of applicable law by the indemnifying Party; (ii) personal injury, death, or loss of or damage
to property caused by the indemnifying Party; (iii) breach of any representations and warranties by the indemnifying Party in Section
6; or (iv) any modification or termination of the applicable TOL License which may materially affect TP’s rights under this
Agreement, unless TP has given prior written consent to such modification or termination, which will not be unreasonably withheld
or delayed.

 

8.2        By
TP. TP will indemnify, defend, and hold harmless TOP and its officers, directors, members, managers, and employees,
from any Losses incurred in relation to a third-party claim arising out of any: (i) gross negligence, willful misconduct, or violation
of applicable law by TP or the TP Contractors; (ii) personal injury, death, or loss of or damage to property caused by TP or the
TP Contractors; or (iii) breach of any representations and warranties by TP in Section 6. TP will indemnify, defend, and hold harmless
TOP and its officers, directors, members, managers, and employees from any Losses incurred in relation to any claim by TOL against
TOP arising out of the TOL License related to activities of TP or the TP Contractors with regards to the Limited Pharmaceutical
Business. TP’s obligations under this Section 8.2 will not apply to the extent a claim is related to TOP’s breach of,
or actions beyond the scope of, the TOL License or this Agreement.

 

    	 	7 	 

     

    

 

8.3        Procedures.
The Party entitled to indemnification for a claim hereunder (the “Indemnified Party”) will promptly give written
notice to the other Party (the “Indemnifying Party”) of such claim, provided that a delay will not affect the
Indemnifying Party’s obligations except to the extent such delay is materially prejudicial to it. The Indemnified Party will
give the Indemnifying Party full control of the defense upon request, and will provide all cooperation and information reasonable
requested by the Indemnifying Party in relation to the defense. The Indemnifying Party will not, without the Indemnified Party’s
prior written consent, enter into any settlement that imposes any non-monetary obligations or liability on the Indemnified Party.

 

9.           LIMITATION
OF LIABILITY.

 

EXCEPT FOR
A PARTY’S INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 8 OR FOR ANY MODIFICATION OR TERMINATION OF A TOL LICENSE THAT
MAY MATERIALLY AFFECT TP’S RIGHTS UNDER THIS AGREEMENT WITHOUT THE ADVANCE WRITTEN CONSENT OF TP, TO THE EXTENT PERMITTED
BY APPLICABLE LAW, NO PARTY SHALL BE LIABLE TO THE OTHER FOR ANY PUNITIVE, EXEMPLARY OR AGGRAVATED, OR ANY INDIRECT OR CONSEQUENTIAL
DAMAGES, IN CONNECTION WITH A BREACH OF THIS AGREEMENT.

 

10.        GENERAL.

 

10.1       Bankruptcy.
The licenses and sublicenses granted to TP hereunder for the Limited Pharmaceutical Business are, for purposes of section
365(n) of the Bankruptcy Code, licenses of rights to “intellectual property,” as that term is defined in section
101 of the Bankruptcy Code. Nothing in this agreement limits TP’s rights under section 365(n), and TP is not making an
election under section 365(n) hereunder.

 

10.2       Cooperation.
The Parties agree to reasonably cooperate with and assist each other in connection with the sublicense granted under this Agreement
and the development and success of commercializing the Sublicensed IP in connection with the Limited Pharmaceutical Business, including
in executing documents and joining in any litigation as needed to ensure proper standing for such litigation.

 

10.3       Notices.
Any notices sent hereunder will be sent by e-mail and internationally-recognized overnight or two (2) day courier to the following
addresses, which may be updated at any time upon ten (10) calendar days’ prior written notice to the other Party:

 

	If to TOP:	TO Pharmaceuticals USA LLC
	 	77 Water Street, 8th Floor
	 	New York, New York 10005
	 	Attn: Chief Executive Officer
	 	Fax: (646) 722-4101
	 	Email: IR@tikunolam.us
	 	 
	with copies to:	Leason Ellis LLP
	 	One Barker Avenue, Fifth Floor
	 	White Plains, New York 10601
	 	Attention: Peter S. Sloane, Esq.
	 	Email: sloane@leasonellis.com
	 	 
	and copies to:	bernie@tikunolam.com and stephen@tikunolam.com
	 	 
	If to TP:	Tikkun Pharma, Inc
	 	2917 Avenue I
	 	Brooklyn, New York 11220
	 	Email: Jeff.Wolfson@haynesboone.com

 

    	 	8 	 

     

    

 

All notices
hereunder may be given by any other means, but shall not be deemed to have been duly given unless and until it is actually received
by the intended recipient.

 

10.4       Governing
Law. THIS AGREEMENT, AND ANY DISPUTE RELATED TO OR ARISING THEREFROM, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE
WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO ANY CHOICE OR CONFLICT OF LAW PROVISION OR RULE (WHETHER
OF THE STATE OF NEW YORK OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE APPLICATION OF LAWS OF ANY JURISDICTION OTHER THAN THOSE
OF THE STATE OF NEW YORK.

 

10.5       Dispute
Resolution. In the event of any dispute, claim, question, or disagreement (“Dispute”)
arising from or relating to this Agreement or the breach thereof, the Parties hereto shall use their best efforts to settle the
dispute, claim, question, or disagreement. To this effect, they shall consult and negotiate with each other in good faith and,
recognizing their mutual interests, attempt to reach a just and equitable solution satisfactory to all Parties. All Disputes not
resolved within fifteen (15) days by good faith negotiation shall be finally settled by arbitration administered by the American
Arbitration Association, in New York, New York, in accordance with the provisions of that organization’s Commercial Arbitration
Rules. The dispute shall be heard and determined by a panel of three (3) arbitrators, unless otherwise agreed by the Parties. In
such case, each Party shall each select one (1) arbitrator. The arbitrator selected by the claimant and the arbitrator selected
by respondent shall, within ten (10) days of their appointment, select a third neutral arbitrator. In the event that they are unable
to do so, or if for any reason the three (3) arbitrators are not timely empanelled, the Parties, or either of them, or their attorneys,
may request that the American Arbitration Association appoint the third or any other necessary arbitrator. Prior to the commencement
of hearings, each of the arbitrators appointed shall provide an oath or undertaking of impartiality. The United States Arbitration
Act shall govern the interpretation, enforcement, and proceedings pursuant hereto. Notwithstanding any provision hereof, any applicable
law or public policy considerations, including without limitation any possible illegality or unenforceability of this Agreement
or any portion hereof due to the subject matter hereof, the arbitrators shall interpret this Agreement giving full effect to the
terms and provisions hereof. All charges of the American Arbitration Association or any mediator shall be borne equally by the
Parties, and each Party hereby agrees to pay all such charges promptly upon request therefor, and if any Party shall fail to do
so, the other Party shall be permitted to apply towards such charges any amounts otherwise due to the non-paying Party. The Parties
to the arbitration proceeding shall bear their own respective expenses incurred in connection therewith, including, but not limited
to, legal fees and expenses.

 

10.6       Waiver.
The waiver by any Party of any breach of covenant will not be construed to be a waiver of any succeeding breach or any other covenant.
All waivers must be in writing, and signed by the Party waiving its rights. This Agreement may be modified only by a written instrument
executed by authorized representatives of the Parties sought to be bound.

 

10.7       Assignment.
Neither Party may assign or transfer this Agreement, in whole or in part, without the prior written consent of the other Party,
which consent will not be unreasonably withheld or delayed. Any purported assignment or transfer in violation of this section will
be null and void. This Agreement will inure to the benefit of, and be binding upon the Parties, together with their respective
legal representatives, successors, and assigns, as permitted herein.

 

10.8       No
Third-Party Beneficiaries. Nothing in this Agreement confers any rights or remedies upon any third party.

 

    	 	9 	 

     

    

 

10.9       Severability.
If any provision of this Agreement is held to be invalid, void, unenforceable, or unconstitutional by a court of competent jurisdiction,
the remaining provisions shall continue in full force without being impaired or invalidated.

 

10.10     Entire
Agreement. This Agreement and the attached Schedule constitutes the entire agreement between the Parties with respect
to the subject matter herein, and supersedes all prior agreements, proposals, negotiations, representations or communications relating
to such subject matter. The Parties acknowledge that they have not been induced to enter into this Agreement by any representations
or promises not specifically stated herein.

 

10.11     Execution;
Counterparts. This Agreement may be executed in counterparts, including electronic counterparts, each of which shall
be deemed to be an original, but all of which together shall constitute one agreement. The headings of the various sections of
this Agreement have been inserted for reference only and shall not be deemed to be a part of this Agreement.

 

The Parties
hereby execute this Agreement as of the Effective Date.

 

	TIKKUN PHARMA, INC.	 	TO PHARMACEUTICALS USA LLC
	 	 	 
	 	 	By: To Pharmaceuticals LLC. its manager
	 	 	By: To Holding Group LLC, its manager
	 	 	By: To Global LLC, its manager
	 	 	 
	By:	/s/ David Stefansky	 	By:	 /s/ Bernard
    Sucher
	 	 	 	 	 
	Name: 	David Stefansky	 	Name:	Bernard Sucher
	 	 	 	 	 
	Title: 	Executive Vice Chairman	 	Title:	Chief Executive Officer

 

[Signature
Page to Amended and Restated Sublicense Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]